Assess whether biosimilarity is analytically justified (0a489f)

Situation

In a company with a CMC site change mid-review, 505(b)(2) literature-to-product bridge table is the evidence after an FAERS cluster in a demographic the trials under-enrolled. Pediatric-plan strategist has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways close using 505(b)(2) literature-to-product bridge table.

Decision

Pediatric-plan strategist in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• The population in 505(b)(2) literature-to-product bridge table is the one an FAERS cluster in a demographic the trials under-enrolled named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in 505(b)(2) literature-to-product bridge table is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; Pause the pathway is the honest Pharma & Life Sciences call.
• A company with a CMC site change mid-review already contained an FAERS cluster in a demographic the trials under-enrolled before 505(b)(2) literature-to-product bridge table arrived; no new CMC and Development Pathways path.
• Provenance on 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pediatric-plan strategist would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move biosimilarity is analytically justified for pediatric-plan strategist.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for pediatric-plan strategist in a company with a CMC site change mid-review.